Clinical Trials Logo

Coronavirus Infections clinical trials

View clinical trials related to Coronavirus Infections.

Filter by:

NCT ID: NCT04548505 Recruiting - SARS-CoV Infection Clinical Trials

Recovery of Exertion Ability Following COVID-19 Infection in Military Staff

CovEx
Start date: October 5, 2020
Phase:
Study type: Observational

The Paris Fire Brigade staff have been particularly exposed to COVID-19 due to rescue and care activities for victims at risk in Paris area (where the virus was actively circulating). In addition, when the pandemic began in France, they had to take care of patients before procedures to protect caregivers were implemented. The contamination of young military personnel, whose physical capacity was put into strain at work, raises the question of the consequences of COVID-19 on their physical fitness. At the time, the medium- and long-term evolution of this disease and its possible repercussions on physical fitness are unknown. Moreover, like any soldiers who have been confined, they may present at least a cardio-respiratory deconditioning (sometimes independent of the disease making it difficult to distinguish between a sequelae of the infection or rehabilitation). Based on previous coronavirus epidemics (Sars-Cov 1 and Mers-Cov), it appears that long-term sequelae are possible even in mild forms and can result in an alteration of exertion ability. In the current context and in the absence of national or international recommendations on the return to physical activity, the French Armed Forces Health Service has proposed a simple management plan aiming at: i) allowing mass screening for possible exercise intolerance and targeting at-risk personnel, ii) allowing individualized re-training and iii) guaranteeing that military personnel can carry out their mission without jeopardizing their health.

NCT ID: NCT04547127 Completed - COVID-19 Clinical Trials

A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

Start date: April 29, 2020
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine if Convalescent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19 requiring admission to the intensive care unit (ICU) through Day 29.

NCT ID: NCT04545047 Completed - Clinical trials for Coronavirus Disease 2019 (COVID-19)

Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19

Start date: May 1, 2020
Phase:
Study type: Observational

The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).

NCT ID: NCT04544878 Recruiting - Covid19 Clinical Trials

Pediatric Intensive Care and COVID-19

CLOVIS
Start date: March 26, 2020
Phase:
Study type: Observational [Patient Registry]

In this prospective longitudinal cohort the investigators reported the clinical, and biological characteristics of all critically ill patients admitted in the pediatric intensive care unit (PICU) of Bicêtre Hospital during the 2019 coronavirus disease (COVID-19) pandemics. Patients were older than 37 weeks of gestational age. No upper limit was set as the unit was transiently converted into a pediatric "adult COVID-19" intensive care unit.

NCT ID: NCT04544072 Recruiting - Clinical trials for Respiratory Tract Infections

Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards

Start date: May 1, 2020
Phase:
Study type: Observational

In this prospective observational study, a quantitative and qualitative analysis of antibiotic prescriptions for presumed respiratory tract (super)infection in patients hospitalized on COVID-19 wards will be made. Drivers of antibiotic prescription for presumed respiratory tract infection in patients suspected of being infected with COVID-19 or with definite COVID-19 infections will be identified.

NCT ID: NCT04542915 Completed - Depression Clinical Trials

COVID-19-Related Health and Practices Among Dental Hygienists

Start date: September 29, 2020
Phase:
Study type: Observational

As dental practices reopen their practices during a global pandemic, the risk of 2019 novel coronavirus (COVID-19) infection that dental hygienists face in providing dental care remains unknown. Estimating the occupational risk of COVID-19, and producing evidence on the types of infection control practices and dental practices that may affect COVID-19 risk, is therefore imperative. These findings could be used to describe the prevalence and incidence of COVID-19 among dental hygienists, determine what infection control steps dental hygienists take over time, describe dental hygienists' employment during the COVID-19 pandemic, and estimate whether infection control adherence in dental practice is related to COVID-19 incidence.

NCT ID: NCT04542538 Completed - Sepsis Clinical Trials

The Impact of Premorbid Illnesses on the Risk of ICU Admission and Short-term Outcome

Start date: April 11, 2018
Phase:
Study type: Observational

The Corona virus disease 2019 (COVID-19) pandemic is currently involving all parts of the world. Several risk factors for critical illness and death from the disease have been proposed. However, it is still unclear if the observed associations between different comorbidities and chronic medications and severe COVID-19 disease and mortality is different from associations between the same factors and other severe diseases requiring intensive care unit (ICU) -care. This is important since some of the observed risk factors are very common in the aged who, by age alone, are more prone to a more severe course of any disease. By combining several registries, this study will compare, on several comorbidities such as hypertension and diabetes , the first 2000 cases of COVID-19 patients receiving critical care in Sweden to a Swedish sepsis-cohort and a Swedish adult respiratory distress syndrome (ARDS) -cohort.

NCT ID: NCT04542395 Withdrawn - Coronavirus Clinical Trials

COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

This proposal seeks to enhance acceptability and uptake of COVID-19 testing and vaccination to engage African American and Latinx public housing residents in South Los Angeles. Given the multiple disparities experienced by public housing residents, the investigators will utilize a theoretically-based, multidisciplinary and culturally tailored intervention to reduce barriers and implement innovate strategies to engage this population in the uptake of COVID-19 testing and vaccination.

NCT ID: NCT04542343 Completed - Coronavirus Clinical Trials

COVID-19 Risk Reduction Among African American Parishioners

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

African American adults, specifically those managing chronic disease and social isolation, are one of the most vulnerable groups susceptible to COVID-19. This intervention involves a multi-disciplinary and culturally sensitive approach to address two major COVID-19 related challenges in this population. First, this program collaborates with predominantly African American churches to implement Federal and State guidelines aimed at preventing outbreaks of COVID-19 at faith-based gatherings. Second, this program trains church-based health advisors to help African American older parishioners manage their chronic health conditions and reduce psychological distress during the pandemic.

NCT ID: NCT04542226 Completed - Clinical trials for Infections, Coronavirus

Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19

Start date: March 31, 2020
Phase:
Study type: Observational

The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections and topical application, 12 mg in hospitalized patients with coronavirus disease (COVID-19).